Investing  in  the future of mental and brain health

INVESTMENT FOCUS

Neurotech & BCI

Digital Health

Precision Psychiatry

Psychedelics & New Compounds

Alternative Modalities

Asset-72

PURPOSE

We fund and support founders revolutionizing brain and mental health through innovative neuroscience and frontier technologies. PsyMed founders align healing, responsibility, and profitability.

 

INVESTMENT FOCUS

We invest in frontier technologies transforming the mental and brain illness epidemic into a flourishing future.

2-1

ARTIFICIAL INTELLIGENCE

 Advanced algorithms and machine learning  to analyze vast data to enable early detection, accurate diagnosis, drug development and personalized treatment

Asset-65

NEUROTECH &
HUMAN AUGMENTATION

Direction connection of technical components with the brain and nervous system are addressing mental health disorders and neurological diseases

Asset-64

PRECISION PSYCHIATRY

Paradigm of clinical care shifting from general approach for large populations to individual-based deep knowledge of clinical and biological characteristics

Asset-69

DIGITAL THERAPEUTICS

Software applications that help patients treat, prevent, or manage a disease, and have a proven clinical benefit

Untitled-design-5

HOLISTIC MEDICINE

Interconnection of biology, psychology, environment, and lifestyle, aiming to address root causes and promote overall well-being

Untitled-design-2

METABOLIC PSYCHIATRY

Bidirectional relationship between metabolic processes and mental health, through diet, exercise, and gut microbiota can impact brain function and psychiatric disorders.

PNC

PSYCHEDELIC MEDICINE
& NEW COMPOUNDS

 Psychedelics (i.e. psilocybin, MDMA, DMT, ketamine) or novel compounds to treat conditions including depression, addiction, PTSD, and more.

Untitled-design-3

DIGITAL HEALTH

 Mobile applications, wearables, and online platforms that enable remote access to mental health services, and facilitate data-driven personalized care

INVESTMENTS

 

Screen Shot 2024-09-19 at 10.02.50 AM

NEURODE

Non invasive neurostimulation and monitoring plafrom, starting with ADHD

Screen Shot 2024-09-19 at 10.02.36 AM

SANMAI

Transcranial focused ultrasound for mental health

STEALTH-NEUROTECH-205-×-142-px-3

STEALTH NEUROTECH

Continuous hormone monitoring

We're donating 4.19% of our profit to psychedelic non-profits and indigenous communities since we are standing on the shoulders of giants.

PEOPLE

Screen Shot 2024-10-09 at 11.31.56 AM

Greg Kubin

General Partner & Co-Founder

Greg is a community builder, investor, and founder. He is a co-host of Business Trip, a podcast exploring the future of mental health and wellness. Over 20 investments in psychedelic medicine and mental health companies. Co-founded HelloSponsor, a SaaS sponsorship platform (AngelPad '15). Ex-Morgan Stanley, Viacom.

Screen Shot 2024-10-09 at 11.31.26 AM

Matias Serebrinsky

General Partner & Co-Founder

Matias is an investor, founder, and startup ecosystem builder. He previously led NVIDIA Inception North America,  an acelerator for AI startups. Before that, he co-founded CookUnity, a food+tech venture backed company that has delivered over one million meals to customers around the country. Matias is the co-host of Business Trip.

Screen Shot 2024-10-09 at 11.43.44 AM

Dina Burkitbayeva

Co-Founder

Dina was one of the first investors in the psychedelic therapeutics space and is on the founding team of the largest psychedelic research center. Dina is also a serial entrepreneur, angel investor (Coinbase, Boom Supersonic, Mattermost), ex-McKinsey/J.P.Morgan, MBA Harvard Business School and MS in Psychology at CIIS.

Screen Shot 2024-10-09 at 11.32.39 AM

Brooks Leitner MD PhD

Partner

Brooks is an investor, founder and physician-scientist. He was previously founder of EpiTET Therapeutics targeting epigenetics to treat chronic disease. He was also a venture fellow at Foresite Capital, BrightEdge, and Canaan. Brooks is an MD PhD from Yale School of Medicine.

Screen Shot 2024-10-09 at 11.33.12 AM

Caitlin Ner

Director of Operations

Caitlin is an operator and community builder. She is also production lead of Business Trip. She was previously founding team of a seed stage AI startup, led insurance growth and operations at Cerebral, and alternative investing and asset management at BlackRock. Caitlin is ex-Harvard in Economics and Computer Science. 

LINKEDIN  |  TWITTER  

Asset-78

Building a company that’s elevating mental health and wellness or looking to get involved as an investor?

SEND US AN EMAIL

PsyMed-Logo-Final

©2022 PSYMED VENTURES. ALL RIGHTS RESERVED.